UB Paderborn / Katalog / Suche / in CDI

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

European urology, 2015-06, Vol.67 (6), p.1028-1038

2015

Link zum Volltext

Verfügbarkeit prüfen

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

The Lancet (British edition), 2018-12, Vol.392 (10162), p.2353-2366

2018

Link zum Volltext

Verfügbarkeit prüfen

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

Trials, 2012-09, Vol.13 (1), p.168-168, Article 168

2012

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

Journal of clinical oncology, 2020-12, Vol.38 (34), p.4064-4075

2020

Link zum Volltext

Verfügbarkeit prüfen

Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

European urology, 2014-11, Vol.66 (5), p.799-802

2014

Link zum Volltext

Verfügbarkeit prüfen

Biological and mechanical evaluation of mineralized-hydrogel scaffolds for tissue engineering applications

Journal of biomaterials applications, 2021-09, Vol.36 (3), p.460-473

2021

Link zum Volltext

Verfügbarkeit prüfen

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer

Journal of clinical oncology, 2022-06, Vol.40 (16), p.1772-1782

2022

Link zum Volltext

Verfügbarkeit prüfen

Physiological Parameter Response to Variation of Mental Workload

Human factors, 2018-02, Vol.60 (1), p.31-56

2018

Link zum Volltext

Verfügbarkeit prüfen

Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707–708

European urology, 2017-07, Vol.72 (1), p.e17-e17

2017

Link zum Volltext

Verfügbarkeit prüfen

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1530-1541

2017

Link zum Volltext

Verfügbarkeit prüfen

Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials

Nature reviews. Urology, 2017-12, Vol.14 (12), p.753

2017

Link zum Volltext

Verfügbarkeit prüfen

Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial

BJU international, 2013-05, Vol.111 (5), p.697-699

2013

Link zum Volltext

Verfügbarkeit prüfen

Recombinant human collagen/chitosan-based soft hydrogels as biomaterials for soft tissue engineering

Materials Science & Engineering C, 2021-02, Vol.121, p.111846-111846, Article 111846

2021

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial

JNCI cancer spectrum, 2022-07, Vol.6 (4)

2022

Link zum Volltext

Verfügbarkeit prüfen

Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer

Human molecular genetics, 2013-02, Vol.22 (4), p.825-831

2013

Link zum Volltext

Verfügbarkeit prüfen

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

European urology oncology, 2018-12, Vol.1 (6), p.449-458

2018

Link zum Volltext

Verfügbarkeit prüfen

Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer

PloS one, 2015-03, Vol.10 (3), p.e0122589-e0122589

2015

Link zum Volltext

Verfügbarkeit prüfen

Penile cancer in the UK: clinical presentation and outcome in 1998/99

BJU international, 2004-12, Vol.94 (9), p.1248-1252

2004

Link zum Volltext

Verfügbarkeit prüfen

Development of tissue engineered ligaments with titanium spring reinforcement

RSC advances, 2016-01, Vol.6 (100), p.98536-98544

2016

Link zum Volltext

Verfügbarkeit prüfen

Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma

Kidney cancer, 2020-01, Vol.4 (4), p.185-195

2020

Link zum Volltext

Verfügbarkeit prüfen

Using type III recombinant human collagen to construct a series of highly porous scaffolds for tissue regeneration

Colloids and surfaces, B, Biointerfaces, 2021-12, Vol.208, p.112139-112139, Article 112139

2021

Link zum Volltext

Verfügbarkeit prüfen

Prospective analysis of scrotal pathology referrals - are referrals appropriate and accurate?

Annals of the Royal College of Surgeons of England, 2006-07, Vol.88 (4), p.363

2006

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

Biological and mechanical evaluation of mineralized-hydrogel scaffolds for tissue engineering applications

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer

Physiological Parameter Response to Variation of Mental Workload

Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707–708

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials

Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial

Recombinant human collagen/chitosan-based soft hydrogels as biomaterials for soft tissue engineering

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial

Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer

Penile cancer in the UK: clinical presentation and outcome in 1998/99

Development of tissue engineered ligaments with titanium spring reinforcement

Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma

Using type III recombinant human collagen to construct a series of highly porous scaffolds for tissue regeneration

Prospective analysis of scrotal pathology referrals - are referrals appropriate and accurate?

Suchergebnisse filtern